CALLIDITAS THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.2 SEK | +0.10% |
|
+81.83% | +63.81% |
| May. 31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
| May. 31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Specialty & Advanced Pharmaceuticals | +0.10% | +81.83% | +63.81% | +122.79% | +323.17% | 1.06B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- CALTX Stock
- Charts Calliditas Therapeutics AB
- Comparison Chart
